|
|
Switzerland Pharmaceuticals and Healthcare Report Q3 2008Published by: Business Monitor International Published: Sep. 15, 2008 - 67 Pages Table of Contents
AbstractSwitzerland’s drug market growth was strong in 2007, following a couple of years worth of second-rateperformance. Indeed, last year saw the market outperforming the European average, in particular itsWestern European counterparts. Much of this improved performance has been down to a strong pace forhigh price patented growth, after two years where lower-priced generics ate into overall market share.Total drug expenditure should continue to show robust growth, reaching a value of CHF6.47bn(US$5.17bn) in 2012. This will be driven by growth in all markets, with generics continuing to gainmarket share, albeit at a slower rate than in recent years.The Swiss biotechnology sector also performed well in 2007, attracting record levels of investment andhealthy revenue growth. Nevertheless profitability remains a lingering problem many biotech firms, a factfrom which Swiss firms are not exempt, and there have been cumulative losses for the industry.The last quarter was dominated by acquisitions and divestments in terms of company activity. Thehighlights of these were Novartis’ US$11bn investment in optalmic group Alcon and US$400mnacquisition of US antibiotic developer Protez Pharmaceuticals. Meanwhile Nycomed decided to divestin its oncology pipeline in order to focus on its main therapeutic areas, including gastroenterology andpain management. The deal will see German firm 4SC take on development of the oncology candidates.The most recent addition to BMI’s reports - the Burden of Disease Database (BoDD) - has highlightedSwitzerland as one of the healthiest countries in Europe. The country ranks fourth among WesternEuropean countries least burdened by disease. Like many of Europe’s more developed states, the leadingcauses of disability-adjusted life years (DALYs) are neuropsychiatric conditions, cancer andcardiovascular diseases. Switzerland remains top of the pile in BMI’s Business Environment Rankings for Western Europe.Despite being a relatively small market, Switzerland’s high per capita spending and strong growth meansthe country scores well, and the country draws on its transparent regulatory environment, strong economyand stable political outlook as its major strengths. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||